Fulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on Tuesday

Fulcrum Therapeutics (NASDAQ:FULC) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Fulcrum Therapeutics Stock Down 2.1%

Fulcrum Therapeutics stock opened at $10.63 on Tuesday. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $15.74. The company’s 50 day moving average price is $11.11 and its two-hundred day moving average price is $9.32. The stock has a market cap of $575.30 million, a P/E ratio of -9.01 and a beta of 3.19.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Piper Sandler restated an “overweight” rating and issued a $23.00 price objective (up previously from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Royal Bank Of Canada increased their price target on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. Cantor Fitzgerald lifted their price objective on shares of Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. HC Wainwright boosted their target price on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $19.11.

Insider Buying and Selling

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. The trade was a 40.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 4,205,139 shares of company stock worth $58,711,943 over the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently modified their holdings of the business. Squarepoint Ops LLC increased its position in shares of Fulcrum Therapeutics by 269.4% during the fourth quarter. Squarepoint Ops LLC now owns 65,852 shares of the company’s stock valued at $745,000 after buying an additional 48,026 shares during the period. Verition Fund Management LLC purchased a new position in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $845,000. Entropy Technologies LP bought a new position in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $136,000. Barclays PLC raised its position in shares of Fulcrum Therapeutics by 47.9% in the 4th quarter. Barclays PLC now owns 132,541 shares of the company’s stock worth $1,499,000 after acquiring an additional 42,925 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter valued at approximately $1,164,000. 89.83% of the stock is owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.